To clarify the effects of active vitamin D 3 on pressor and vascular responses to vasoconstrictor substances, we studied pressor responses to the intravenous injection of norepinephrine or angiotensin II (Ang II) and vasoconstrictor responses to norepinephrine. Sprague-Dawley rats were given 1,25 -dihydroxyvitamin D 3 subcutaneously (200 ng/kg per day) for 14 days. The administration of 1,25-dihydroxyvitamin D, augmented the pressor responses to norepinephrine and Ang II in conscious rats and was associated with a significant increase in serum calcium concentration (11.0±0.2 mg/dl). To further clarify whether the increased pressor response to vasoconstrictors may be due to the calcemic or direct action of active vitamin D 3 , we studied the effect of its noncalcemic analogue, 22-oxacalcitriol, and its inactive analogue, 24,25-dihydroxy vitamin D } , on the pressor response to vasoconstrictors in rats. The pressor responses to norepinephrine and Ang II were apparently augmented in 22-oxacalcitriol-treated rats similarly to 1,25-dihydroxyvitamin D 3 -treated rats. In contrast, the pressor responses were not affected by either 24,25-dihydroxy vitamin D 3 or the intravenous infusion of calcium chloride. In an ex vivo experiment using a mesenteric preparation, the vascular sensitivity to norepinephrine was moderately augmented in rats treated with both 22-oxacalcitriol and 1,25-dihydroxyvitamin D 3 but was not affected in rats treated with 24,25-dihydroxyvitamin D 3 . The results suggest that the enhanced pressor responses to norepinephrine and Ang II could be attributed to the direct effect of active vitamin D, on vasculature rather than to hypercalcemia. the calcemic effect of 1,25(OH) 2 D 3 might in some way contribute to the increased pressor action of the active vitamin D 3 . Elevation of serum calcium concentration in forearm blood flow with intrabrachial infusion of calcium not only increased basal forearm vascular resistance but also augmented the forearm vascular responses to vasoactive substances in humans.
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To clarify the effects of active vitamin D 3 on pressor and vascular responses to vasoconstrictor substances, we studied pressor responses to the intravenous injection of norepinephrine or angiotensin II (Ang II) and vasoconstrictor responses to norepinephrine. Sprague-Dawley rats were given 1,25 -dihydroxyvitamin D 3 subcutaneously (200 ng/kg per day) for 14 days. The administration of 1,25-dihydroxyvitamin D, augmented the pressor responses to norepinephrine and Ang II in conscious rats and was associated with a significant increase in serum calcium concentration (11.0±0.2 mg/dl). To further clarify whether the increased pressor response to vasoconstrictors may be due to the calcemic or direct action of active vitamin D 3 , we studied the effect of its noncalcemic analogue, 22-oxacalcitriol, and its inactive analogue, 24,25-dihydroxy vitamin D } , on the pressor response to vasoconstrictors in rats. The pressor responses to norepinephrine and Ang II were apparently augmented in 22-oxacalcitriol-treated rats similarly to 1,25-dihydroxyvitamin D 3 -treated rats. In contrast, the pressor responses were not affected by either 24,25-dihydroxy vitamin D 3 or the intravenous infusion of calcium chloride. In an ex vivo experiment using a mesenteric preparation, the vascular sensitivity to norepinephrine was moderately augmented in rats treated with both 22-oxacalcitriol and 1,25-dihydroxyvitamin D 3 but was not affected in rats treated with 24,25-dihydroxyvitamin D 3 . The results suggest that the enhanced pressor responses to norepinephrine and Ang II could be attributed to the direct effect of active vitamin D, on vasculature rather than to hypercalcemia. the calcemic effect of 1,25(OH) 2 D 3 might in some way contribute to the increased pressor action of the active vitamin D 3 . Elevation of serum calcium concentration in forearm blood flow with intrabrachial infusion of calcium not only increased basal forearm vascular resistance but also augmented the forearm vascular responses to vasoactive substances in humans. 10 In addition to its calcemic effect, 1,25(OH) 2 D 3 has noncalcemic effects, such as stimulating cell differentiation," depressing parathyroid hormone, 12 and enhancing the immune response. 13 We therefore should consider both noncalcemic and calcemic effects as contributing to the vasoconstrictive action of 1,25(OH) 2 
Methods
Protocol 1
Forty 8-week-old male Sprague-Dawley rats (body weight, 200-250 g; Charles River Japan, Atsugi, Japan) were subjected to continuous infusion of 200 Fourteen days after treatment, the rats were anesthetized with ether, and the carotid artery and jugular vein were cannulated with PE-50 polyethylene tubing. The arterial and venous catheters were tunneled to the back of the neck, filled with heparinized saline (100 units/ml), and plugged with stainless steel pins. Rats were left for 3 hours until the effect of anesthesia disappeared. The carotid arterial catheter was flushed and attached to a pressure transducer (model TP-200T, Nihon Kohden, Tokyo), and blood pressure and heart rate were recorded on a thermal array recorder (model WS-641G, Nihon Kohden). Carotid arterial pressure was measured as mean arterial pressure (MAP).
After basal MAP and heart rate measurement, norepinephrine (10~8, 10" 7 , and 0.5 xlO" 6 mol/kg) or Ang II (12.5, 25, and 50 ng/kg) dissolved in 0.1 ml saline was injected into the jugular vein as a bolus. The peak values of increases in MAP were considered as the response to each dose of the vasoconstrictor. Each injection was done 15 minutes after MAP returned to basal level. After the pressor response experiment, blood samples were taken for measurement of serum calcium level.
Protocol 2
Eight age-matched male Sprague-Dawley rats were anesthetized as in protocol 1, and the carotid artery and jugular vein were cannulated as described above. Then, 14.7 mg per 4.7 ml per hour of calcium chloride (CaCl 2 ) or saline was infused intravenously for 30 minutes while MAP and heart rate were monitored as in protocol 1. This dose of CaCl 2 produced a similar level of serum calcium as 1,25(OH) 2 D 3 treatment ( Table 1 ). The same doses of norepinephrine or Ang II as described above were infused, and changes in MAP were recorded. After injections, blood samples were taken for measurement of serum calcium concentration.
Protocol 3
In twenty-three Sprague-Dawley rats, 1,25(OH) 2 D 3 , OCT, 24,25(OH) 2 D 3 , or propylene glycol was administered in the same manner as in protocol 1. Fourteen days after treatment, the rats were anesthetized with sodium pentobarbital (60 mg/kg i.p.), and the intestinal loop containing the mesenteric artery was prepared with a modified form of Castellucci's method. 14 The abdominal cavity was opened, the superior mesenteric artery was located, and the proximal segment was cleaned of surrounding tissue in the area of the aorta. A PE-50 polyethylene catheter was inserted distally into the main trunk of the mesenteric artery at its origin from the aorta and was tied in place. The mesenteric vasculature was flushed with approximately 3 ml heparinized Krebs-Henseleit solution, and then the large intestine was isolated and discarded. The entire mesenteric-intestinal loop was cut and quickly connected to the perfusion apparatus. The preparations were perfused with Krebs-Henseleit solution by use of a peristaltic pump (Minipuls 2, Gilson Medical Electronics SA, Villiers-le-Bel, France) at a rate of 3 ml/min. Constituents of the solution were as follows (mmol/1): NaCl 114.5, KC1 4.6, KH 2 PO 4 1.4, MgSO 4 2.4, CaCl 2 2.5, NaHCO 3 25, and glucose 5.6. The solution was continuously oxygenated with a gas mixture of 95% O 2 -5% CO 2 at 37°C. A 30-minute equilibration period was allowed before each experiment was started. Norepinephrine in a dose of 5,10, 50, or 100 /j,mol was injected as a bolus with a microinjector. The change of perfusion pressure was recorded by a pressure transducer (model TP-200T, Nihon Kohden) connected to a thermal array recorder (model WS-641G, Nihon Kohden). Percent change of perfusion pressure was then calculated.
Drugs
We used OCT as a noncalcemic analogue of 1,25(OH) 2 12 and enhances the immune response in mice. 13 In contrast, OCT was at least 100 times less calcemic than 1,25(OH) 2 D 3 in normal rats 12 and in mice. 13 
Statistical Methods
All data are expressed as mean±SEM. Data were analyzed with a two-way analysis of variance, and subsequent multiple comparison was done by Scheffe's method. Statistical significance was defined at a value of p<0.05.
Results
Protocol 1
Body weight, basal MAP, heart rate, and serum calcium concentrations are shown in Table 1 . Among the five experimental groups, body weight, MAP, and heart rate did not differ. Serum calcium levels were significantly higher in the 1,25(OH) 2 D 3 group than in the control group (p<0.01). Serum calcium levels in OCT-or 24,25(OH) 2 D 3 -treated rats, however, did not significantly differ from those in vehicle-treated control rats.
In vehicle-treated rats, norepinephrine injected at the doses of 10~8, 10~7, and 0.5 xlO" 6 mol/kg increased MAP in a dose-dependent fashion (7±2, 9±1, and 18±2 mmHg, respectively (Figure 1 ). 1,25(OH) 2 D 3 treatment enhanced the pressor effect of norepinephrine (11±1, 20±l, and 39±1 mmHg; p<0.01), but 24,25(OH) 2 D 3 did not (4±1, 8±1, and 17±2 mmHg; NS). Despite unchanged serum calcium levels, the increases of MAP with norepinephrine were significantly greater in OCT-treated rats than in control rats (12±1, 18±1, and 31+2 mm Hg;/?<0.01). The percent decrease of heart rate was -16 ±14%, -28 ±15%, and -36±16% in the control group and -15±16%, -16+16%, and -39±15% in the 24,25(OH) 2 D 3 group. Corresponding to enhanced pressor response, the decrease in heart rate was greater in the 1,25(OH) 2 (Table 2 ). According to the changes in MAP, heart rate decreased greatly with infusion of norepinephrine or Ang II in both 1,25(OH) 2 D 3 -and OCT-treated rats as compared with vehicle-or 24,25(OH) 2 D 3 -treated rats (Table 2) .
Protocol 2
Basal MAP was not different between rats infused with saline (108+1 mmHg) or CaCl 2 (107±l mmHg) ( Table 1) . CaCl 2 -infused rats showed elevated serum calcium levels similar to those of the 1,25(OH) 2 D 3 -treated rats (Table 1) . Both norepinephrine and Ang II caused dose-dependent increases in MAP. In CaCl 2 -versus saline-infused rats, there was no significant difference in pressor response to either norepinephrine (2±1 versus 2±1, 11±1 versus 10±l, and 16±2 versus 16±2 mmHg; NS) ( Figure 1 ) or Ang II (4±1 versus 3±1, 9±1 versus 9±1, and 15±2 versus 14±2 mm Hg; NS). The decrease of heart rate with norepinephrine or Ang II was not significantly different between the two groups (data not shown).
Protocol 3
Body weight [315±1, 288±5, 305±4, and 303±4 g; control, 1,25(OH) 2 D 3 , OCT, and 24,25(OH) 2 D 3 , respectively] and serum calcium level (9.6±0.1, 11.1 ±0.2, 9.9±0.2, and 10.0±0.2 mg/dl, respectively) showed similar tendencies to those in protocol 1. Changes of perfusion pressure with norepinephrine at 5,10, 50, and 100 fimo\ were significantly greater in the 1,25(OH) 2 D 3 group (33.8±4.1%, 61.3±4.7%, 113.0±5.6%, and 160.2±6.3%; p<0.01) and OCT group (22.5±2.9%, 76.1±11.6%, 128.8±5.2%, and 182.5±5.6%; p<0.01) than in the control group (14.6±0.8%, 24.6±1.7%, 44.9±6.1%, and 83.6±4.6%) (Figure 2) . 24,25(OH) 2 D 3 did not change incremental responses of perfusion pressure to norepinephrine (15.6±1.9%, 30.6±9.8%, 45.7+6.1%, and 76.3±5.1%) (Figure 2 ).
Discussion
Our first observation that 1,25(OH) 2 D 3 enhances pressor responses to both norepinephrine and Ang II is consistent with the previous study by Bukoski et al. 6 The most important finding is that a noncalcemic analogue, OCT, 11 -131516 not only enhanced the pressor response to vasoactive substances but also augmented the incremental responses of perfusion pressure to norepinephrine to the same degree as the administration of 1,25(OH) 2 D 3 in the mesenteric artery preparation. These results suggest that l,25(OH) 2 D 3 -induced augmentation of pressor and vascular responses to vasoconstrictors may be due to the noncalcemic effect of active vitamin D 3 .
The noncalcemic analogue OCT has the same physiological activity as 1,25(OH) 2 D 3 , lowering bone calcium mobilizing activity 16 and suppressing parathyroid hormone synthesis and secretion. 13 OCT does not elevate intracellular calcium, although 1,25(OH) 2 D 3 increases intracellular and extracellular calcium. 1718 OCT was then used to investigate the noncalcemic effects of 1,25(OH) 2 D 3 . In fact, treatment with OCT could enhance pressor responses to norepinephrine and Ang II despite no apparent increase in serum calcium concentration. This suggests that 1,25(OH) 2 D 3 enhances the pressor effect to vasoconstrictive agents through its noncalcemic effect. In the present study, we did not measure 1,25(OH) 2 D 3 level, but the effect of OCT must not be mediated through a secondary increase in 1,25(OH) 2 D 3 , because OCT has been reported to decrease 1,25(OH) 2 D 3 level.
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- 20 We suggest that the enhancing effect of OCT on pressor action may not be mediated through increasing 1,25(OH) 2 D 3 .
This hypothesis is also supported by the results of the calcium infusion study. Calcium infusion did not affect pressor responses to norepinephrine and Ang II, although serum calcium concentration was elevated to the same level as in l,25(OH) 2 D 3 -treated rats. Some investigators 2122 demonstrated that intravenous infusion of a high dose of calcium could enhance pressor effects by norepinephrine. In humans, 21 pressor responses to norepinephrine were not enhanced until serum calcium levels reached 13.0±0.5 mg/dl, levels that were much higher than those in the l,25(OH) 2 D 3 -treated rats in our study (11.0±0.2 mg/dl, p<0.01, Student's unpaired t test). Moreover, in vitro study with femoral artery rings from deoxycorticosterone acetate-salt and Sprague-Dawley rats revealed that high extracellular ionized calcium (2.5 mM) enhanced vasoconstriction by KC1 and norepinephrine compared with low calcium (0.25 mM). 22 The mild increase in plasma calcium level (11.2±1.0 mg/dl), although similar to that in our study (11.0±0.2 mg/dl), did not affect pressor responses to norepinephrine and Ang II in normal subjects. 23 Thus, the 1,25(OH) 2 D 3 dosing used in this study may enhance pressor responses to norepinephrine and Ang II independent of the elevation of serum calcium level. In addition, the administration of 24,25(OH) 2 D 3 , an inactive vitamin D 3 analogue, 24 had no effect on pressor responses to norepinephrine and Ang II, suggesting that pressor enhancement by 1,25(OH) 2 D 3 is not due to its nonspecific action.
Because of the augmentation of responses to norepinephrine by 1,25(OH) 2 D 3 , we can speculate that 1,25(OH) 2 D 3 can modulate sympathetic tone directly, because norepinephrine release at presynaptic nerve endings depends on its intracellular calcium concentration. 25 However, Baksi and Hughes 26 reported that vitamin D supplementation did not affect norepinephrine release or metabolism. In fact, in the present study, the changes in heart rate with infusion of norepinephrine or Ang II corresponded to those in MAP, suggesting that baroreceptor function is not affected by the treatments. l,25(OH) 2 D 3 -induced enhancement of the pressor response to norepinephrine might not be attributed to changes in sympathetic tone, although the effect of active vitamin D 3 on norepinephrine release was not examined. The results of the present study suggest that increased pressor response to norepinephrine by 1,25(OH) 2 D 3 may be the result of enhanced vascular smooth muscle cell contractility through nonspecific agonist-mediated receptor reaction. This hypothesis is supported by the present finding that 1,25(OH) 2 D 3 could augment not only the pressor response to norepinephrine but also that to Ang II.
Norepinephrine-or Ang II-induced contraction of vascular smooth muscle cell is dependent on an increased concentration of intracellular free ionized calcium. But, in our study, OCT, which does not elevate intracellular calcium in either nongenomic 17 or genomic pathways, 18 augmented vascular responsiveness. The possible role of changes in intracellular calcium level, however, is still unknown, and further study is required.
Recent studies on vasoactive substances and endothelium lead us to conclude that endothelial function is one of the important factors in regulating vascular tone. 27 ' 28 It is known that there are 1,25(OH) 2 D 3 receptors on endothelial cells. 29 Although little is known about the effect of 1,25(OH) 2 D 3 on endothelial function, hypervitaminosis D in rats caused endothelial degeneration. 30 In contrast, a recent study by Xue et al 3 ' indicated that 1,25(OH) 2 D 3 preserved endothelial function in culture conditions. In in vitro conditions, vascular relaxation with acetylcholine is well preserved when active vitamin D 3 is added in media. Our study conditions are different from the conditions in the report of Xue et al, 31 but releasing ability of endothelium-derived relaxing factor might not be the cause of the vasoconstriction observed. The apparently discrepant results may be due to different experimental conditions between our study and Xue's. The noncalcemic effect of 1,25(OH) 2 D 3 on endothelial function still remains to be determined. 30 If the administration of 1,25(OH) 2 D 3 and OCT in rats could cause vascular hypertrophy, it may also be involved in the increased pressor and vascular responses to norepinephrine and Ang II through the changes in vascular wall-to-lumen ratio. Further investigations are required to clarify these possibilities.
In conclusion, long-term treatment with 1,25(OH) 2 D 3 in rats enhanced pressor responses to norepinephrine and Ang II. This was intimately related to the increased vascular reactivity to a vasoconstrictor, possibly through the noncalcemic effect of 1,25(OH) 2 D 3 .
